ImmunityBio, Inc.

NASDAQ:IBRX

Biotechnology

Healthcare
$6.70 +2.58%

+$0.18 today

Market cap
$7.13B
Beta
0.10
P/E (TTM)
-8.6
EPS (TTM)
-$0.83
52W Low $1.95High $12.43

Volume 15.77M

Average 16.40M

IBRX Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

ImmunityBio, Inc.NASDAQ: IBRX

Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026

Depreciation & amortization dips below year-ago levels

Q3 FY2026 depreciation & amortization of $3.89M fell 1.6% year over year, behind the +4.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 11.8% from the prior quarter. Over 3 fiscal years it compounded at -5.3% a year.

Context

  • Depreciation & amortization amounted to 13.7% of revenue in FY2025, down 105.3 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -1.6% toward the trailing-twelve-month pace of +4.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$3.89M-11.8% QoQ
Last fiscal yearDec 2025
$15.53M-11.6% YoY
LTMSep 2026
$16.54M+4.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.6%——
1 year-11.6%——
3-year CAGR-5.3%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
15.53M USD
Year-over-year change
-11.6%
4-year CAGR
+2.2%

Depreciation & Amortization vs competitors

How IBRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +4.6% is the 4th highest of 11, against a peer median of -5.0%.
  • Depreciation & amortization amounts to 9.1% of revenue for IBRX, versus a peer median of 10.8%.
IBRX Competitors
Depreciation & Amortization for IBRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€676.85M EUR+122.9%+43.9%25.6%
MRNAModerna, Inc.LTM Sep 2026$257M USD+23.6%-14.8%10.2%
LEGNLegend Biotech CorporationLTM Sep 2026$50.27M USD+111.9%+16.3%3.7%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$42.96M USD-7.4%+30.8%11.3%
IBRXImmunityBio, Inc.LTM Sep 2026$16.54M USD+4.6%-5.3%9.1%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$12.13M USD-8.0%-4.7%—
IMTXImmatics N.V.LTM Mar 2026€12.04M EUR-2.6%+21.9%32.3%
VIRVir Biotechnology, Inc.LTM Mar 2026$11.62M USD-10.0%+19.9%17.7%
NKTXNkarta, Inc.LTM Mar 2026$9.23M USD+0.4%+51.6%—
IMCRImmunocore Holdings plcLTM Mar 2026$3.14M USD-22.4%-18.0%0.8%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$350K USD-93.6%-27.9%1.5%
Peer median (excluding IBRX) —-5.0%+18.1%10.8%

Competitors are the stored peer set for IBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue934K240K622K14.75M113.29M
Cost of Revenue0000753K
Gross Profit934K240K622K14.75M112.54M
Gross Margin100.0%100.0%100.0%100.0%99.3%
Research & Development195.96M248.15M232.37M190.14M207.88M
Selling, General & Admin135.26M102.71M129.62M168.78M147.18M
Operating Expenses331.21M351.54M362.87M358.93M368.56M
Depreciation & Amortization14.24M18.26M18.51M17.55M15.53M
EBITDA(320.75M)(351.88M)(478.66M)(264.43M)(223.56M)
EBITDA Margin-34341.8%-146617.1%-76955.5%-1793.4%-197.3%
Operating Income(330.28M)(351.3M)(362.25M)(344.18M)(256.03M)
Operating Margin-35361.9%-146374.2%-58239.5%-2334.2%-226.0%
Interest Income836K2.71M863K2.4M6.7M
Interest Expense14.85M47.15M86.72M131.66M112.53M
Other Income / Expenses(19.56M)(65.99M)(221.64M)(69.46M)(95.58M)
Income Before Tax(349.84M)(417.29M)(583.89M)(413.65M)(351.61M)
Pre-Tax Margin-37456.0%-173869.2%-93873.3%-2805.3%-310.4%
Income Tax Expense9K34K(40K)0(135K)
Net Income(346.79M)(416.57M)(583.2M)(413.56M)(351.4M)
Net Margin-37129.6%-173569.6%-93761.4%-2804.8%-310.2%
EPS (Basic)(0.89)(1.04)(1.15)(0.59)(0.38)
EPS (Diluted)(0.89)(1.04)(1.15)(0.62)(0.38)
Weighted Avg Shares389.23M399.9M508.64M697.31M919.86M
Weighted Avg Shares (Diluted)389.23M399.9M508.64M700.44M919.86M

ImmunityBio, Inc.

NASDAQ:IBRX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.